Pipeline – Cancer Drug Programmes

At Sareum, structure-based technologies are being combined with a history of pharmaceutical expertise to discover, optimize and advance a sustainable pipeline of best-in-class and first-in-class small molecule inhibitors for the treatment of cancer.

The human body is usually an extremely well regulated organism continually fighting attack from injury and disease to maintain good health. So the emergence of cancer is due to many facets of the body's regulatory system being overcome in order for the disease to prevail. For this reason providing treatment that attacks a cancer in more than one way provide a greater chance of therapeutic success.

Sareum's strategy for generating new treatments for cancer is three-pronged. Firstly we are working on novel drugs which target single enzyme pathways within cancer cells, which will then be used in combination with existing drugs to greatly improve the effect of these drugs (Chk1, PLK & B-raf). Secondly we are working on drugs, that simultaneously target several different biochemical pathways (Aurora/Flt) which will then be used as single agent therapies in cancer patients refractory to current drug treatments. Thirdly, we are working on a therapeutic approach, via inhibition of the enzyme FLT4, to regulate the process of metastasis, the main cause of death from cancer.

All of these programmes are available for partnering.

*Chk1 is a joint discovery programme between Sareum, The Institute for Cancer Research (ICR) and Cancer Research Technologies (CRT).